Payment overview · 2025
General Payments
$1,521.41
30 reported records · 15 companies
Healthcare provider profile · identity verified
Yiling Zeng, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · NEW YORK, NY · NPI 1922348390
Verified facts
What the public records show
CMS Open Payments records show Yiling Zeng, NP received $1,521.41 in general payments during 2025 across 30 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Nexletol, Prolia, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nexletol by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $436.76 | 28.7% | 6 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $361.29 | 23.8% | 6 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $150.00 | 9.9% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $137.78 | 9.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 8.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.17 | 3.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.34 | 3.5% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.36 | 2.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$28.13 | 1.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.25 | 1.7% | 1 | 2025 |
| AGEPHA Pharma FZ LLC | Unresolved — no canonical attribution shown | $25.00 | 1.6% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $25.00 | 1.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.09 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.83 | 1.4% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.41 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,521.41 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $268.62 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $168.14 | 3 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $137.78 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $124.26 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $59.17 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $53.34 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $47.34 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $34.36 | 2 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| LODOCO Normalized: lodoco |
Drug | AGEPHA Pharma FZ LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 105 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 17 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
140 | 55 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 38 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
42 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 943 | 413 |
| Vascepa | Icosapent Ethyl | 795 | 260 |
| Losartan Potassium | Losartan Potassium | 492 | 210 |
| Amlodipine Besylate | Amlodipine Besylate | 459 | 172 |
| Diclofenac Epolamine | Diclofenac Epolamine | 456 | 135 |
| Tamsulosin Hcl | Tamsulosin Hcl | 352 | 134 |
| Omeprazole | Omeprazole | 331 | 138 |
| Donepezil Hcl | Donepezil Hcl | 329 | 152 |
| Metformin Hcl | Metformin Hcl | 325 | 123 |
| Montelukast Sodium | Montelukast Sodium | 261 | 95 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 254 | 90 |
| Fluticasone Propionate | Fluticasone Propionate | 234 | 98 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 219 | 62 |
| Meclizine Hcl | Meclizine Hcl | 218 | 146 |
| Ammonium Lactate | Ammonium Lactate | 215 | 90 |
| Meloxicam | Meloxicam | 207 | 132 |
| Azithromycin | Azithromycin | 204 | 180 |
| Alendronate Sodium | Alendronate Sodium | 198 | 88 |
| Raloxifene Hcl | Raloxifene Hcl | 187 | 61 |
| Finasteride | Finasteride | 185 | 80 |
| Trazodone Hcl | Trazodone Hcl | 171 | 80 |
| Diclofenac Sodium | Diclofenac Sodium | 166 | 107 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 165 | 79 |
| Halobetasol Propionate | Halobetasol Propionate | 160 | 96 |
| Simvastatin | Simvastatin | 156 | 68 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 151 | 50 |
| Farxiga | Dapagliflozin Propanediol | 140 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 60 |
| Lisinopril | Lisinopril | 136 | 55 |
| Gabapentin | Gabapentin | 132 | 51 |
| Bepotastine Besilate | Bepotastine Besilate | 118 | 33 |
| Famotidine | Famotidine | 109 | 34 |
| Jardiance | Empagliflozin | 105 | 38 |
| Januvia | Sitagliptin Phosphate | 103 | 35 |
| Ezetimibe | Ezetimibe | 98 | 49 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 95 | 46 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 87 | 42 |
| Clotrimazole | Clotrimazole | 85 | 21 |
| Synthroid | Levothyroxine Sodium | 85 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | 29 |
| Celecoxib | Celecoxib | 75 | 47 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 72 | 21 |
| Mometasone Furoate | Mometasone Furoate | 72 | 31 |
| Azelastine Hcl | Azelastine Hcl | 71 | 25 |
| Mupirocin | Mupirocin | 71 | 55 |
| Allopurinol | Allopurinol | 66 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 38 |
| Clobetasol Propionate | Clobetasol Propionate | 60 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 60 | 32 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 59 | 28 |
| Metformin Hcl Er | Metformin Hcl | 58 | 20 |
| Amoxicillin | Amoxicillin | 57 | 53 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 57 | 19 |
| Hydrocortisone | Hydrocortisone | 51 | 29 |
| Vemlidy | Tenofovir Alafenamide | 50 | suppressed |
| Licart | Diclofenac Epolamine | 49 | suppressed |
| Loperamide | Loperamide Hcl | 49 | 38 |
| Eliquis | Apixaban | 47 | 13 |
| Folic Acid | Folic Acid | 46 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 46 | 22 |
| Icosapent Ethyl | Icosapent Ethyl | 45 | 23 |
| Acarbose | Acarbose | 44 | 13 |
| Denta 5000 Plus | Fluoride (Sodium) | 44 | suppressed |
| Glipizide Er | Glipizide | 44 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 42 | 31 |
| Glimepiride | Glimepiride | 41 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 16 |
| Ketoconazole | Ketoconazole | 40 | 18 |
| Procto-Med Hc | Hydrocortisone | 39 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | 11 |
| Naproxen | Naproxen | 36 | 21 |
| Enalapril Maleate | Enalapril Maleate | 35 | 12 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 30 |
| Dexlansoprazole Dr | Dexlansoprazole | 34 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 20 |
| Olanzapine | Olanzapine | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Fluocinonide | Fluocinonide | 30 | 12 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 30 | suppressed |
| Carvedilol | Carvedilol | 29 | 15 |
| Memantine Hcl Er | Memantine Hcl | 29 | suppressed |
| Creon | Lipase/Protease/Amylase | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Atenolol | Atenolol | 26 | 15 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 25 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 24 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 18 |
| Fenofibrate | Fenofibrate,micronized | 23 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | 12 |
| Dutasteride | Dutasteride | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | 11 |
| Ciclopirox | Ciclopirox | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Nexletol | Bempedoic Acid | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 18 | 18 |
| Ibuprofen | Ibuprofen | 18 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Prolia | Denosumab | 17 | 14 |
| Repaglinide | Repaglinide | 17 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 17 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 16 | 16 |
| Bepreve | Bepotastine Besilate | 16 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | 12 |
| Nexium | Esomeprazole Magnesium | 15 | suppressed |
| Proctozone-Hc | Hydrocortisone | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Sodium Fluoride 5000 Plus | Fluoride (Sodium) | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | suppressed |
| Xiidra | Lifitegrast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,521.41 · 30 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Attruby, Auvelity, BREZTRI, EVENITY, Fluad, Flucelvax, IBSRELA, JARDIANCE, LODOCO, Livdelzi, NEXLETOL, PERCEPT PC BRAINSENSE, PROLIA, PYRUKYND, REXULTI, TRELEGY ELLIPTA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error